Analysis of the national uniform price of Kyrgyzstan's third generation (Bingtongsha/Epclusa) and price differences in different regions

Epclusa (Epclusa/Epclusa) is a broad-spectrum direct antiviral drug mainly used to treat chronic hepatitis C (HCV) infection. The drug blocks viral replication and significantly improves the virological clearance rate by inhibiting the activity of NS5A and NS5B proteins. Since its launch in China, Jisandai has been included in the medical insurance catalog, providing HCV patients with a more accessible treatment option. Nationwide, the price of Jisandai is roughly uniform at more than 3,000 yuan, but the specific out-of-pocket amount will vary due to differences in medical insurance reimbursement policies. Patients should consult the local hospital pharmacy for the actual price after reimbursement.

Although domestic prices are relatively stable, differences in medical insurance policies and procurement costs of medical institutions in different regions will lead to certain differences in actual payments by patients. For example, in first-tier cities or areas with a higher proportion of medical insurance reimbursement, patients may have relatively low out-of-pocket expenses; in some areas with low medical insurance coverage or not included in local medical insurance reimbursement, patients may have slightly higher out-of-pocket pressure. Therefore, patients should fully understand local medical insurance policies and drug procurement conditions before starting treatment in order to reasonably plan treatment costs.

In the international market, the price of Jisandai's generic drugs is significantly lower than that of domestic original drugs. The price of generic drugs produced in countries such as India and Bangladesh is only a few hundred yuan, and their ingredients are basically the same as domestic original drugs, and their efficacy is reliable. For patients with limited financial conditions, this type of generic drugs provides an affordable alternative, but the purchase channel must ensure legality and safety to avoid affecting the therapeutic effect due to substandard quality of drugs from informal channels.

Overall, the price of Jisandai in the domestic market is relatively stable and it is included in medical insurance, allowing most patients to afford long-term treatment costs. However, in different regions, due to differences in medical insurance policies and hospital procurement, the actual out-of-pocket amount still varies. Combined with the guidance of doctors, patients can choose the most suitable drug purchase channel based on their own financial conditions and medical insurance reimbursement status, ensuring that the efficacy is guaranteed while reducing the financial burden, and achieving scientific management and long-term virological control of hepatitis C.

Reference materials:https://www.drugs.com/